A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
- 28 November 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 114 (22), 2374-2381
- https://doi.org/10.1161/circulationaha.106.642074
Abstract
Background— Rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—could be an alternative to heparins and warfarin for the prevention and treatment of thromboembolic disorders. Methods and ...Keywords
This publication has 17 references indexed in Scilit:
- Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacementJournal of Thrombosis and Haemostasis, 2005
- Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjectsEuropean Journal of Clinical Pharmacology, 2005
- Effects of Single-Dose BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor - in Subjects with Extreme Body Weight.Blood, 2005
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005
- Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorCancer Cell, 2005
- Pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogsXenobiotica, 2005
- Prevention of Venous ThromboembolismChest, 2004
- Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trialThe Lancet, 2002
- Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trialsActa Radiologica, 1997
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972